Lantheus Holdings LNTH
NASDAQ LNTH
$99.97 -0.27 (-0.27%)
At close: Aug 21, 2026 · 4:00 PM EDT

Lantheus Holdings (LNTH) Asset Writedowns and Impairment (2014 - 2026)

Lantheus Holdings (LNTH) posted quarterly Asset Writedowns and Impairment of $1.5 million for Q1 2026, up 211.54% year-over-year from $493358.0 in Q1 2025, and up 330.43% quarter-over-quarter from -$667000.0 in Q4 2025.

Lantheus Holdings (LNTH) Asset Writedowns and Impairment (2014 - 2026) Analysis & Trends

Lantheus Holdings (LNTH) has reported Asset Writedowns and Impairment for 13 consecutive years, with $1.5 million the latest figure, recorded in Q1 2026.

  • In Q1 2026, Asset Writedowns and Impairment rose 211.54% year-over-year to $1.5 million; the TTM figure through Mar 2026 stood at $5.1 million (up 223.75% YoY), while the FY2025 annual figure was $2.2 million, changed N/A from the prior year.
  • Asset Writedowns and Impairment improved to $1.5 million in Q1 2026 per LNTH's latest filing, from -$667000.0 in the prior quarter.
  • Across five years, Asset Writedowns and Impairment topped out at $132.1 million in Q1 2023 and bottomed at -$1.4 million in Q1 2025.
  • Historically, Asset Writedowns and Impairment has averaged $12.4 million across 5 years, with a median of $1.7 million in 2025.
  • Annual changes were most pronounced in 2022 — Asset Writedowns and Impairment surged 3680.42% — and 2025, when it tumbled 149.98%.
  • Lantheus Holdings' Asset Writedowns and Impairment stood at $7.1 million in 2022, then retreated by 16.05% to $6.0 million in 2023, then plunged by 112.3% to -$738000.0 in 2024, then increased by 9.62% to -$667000.0 in 2025, then surged by 330.43% to $1.5 million in 2026.
  • Business Quant data shows LNTH's Asset Writedowns and Impairment at $1.5 million in Q1 2026, -$667000.0 in Q4 2025, and $1.9 million in Q3 2025.

Peer Comparison

# Company Market Cap Enterprise Value Gross Profit (Qtr)
1 Haleon 44.51 Bn 43.55 Bn -
2 Teva Pharmaceutical Industries 43.52 Bn 39.86 Bn 2.15 Bn
3 Zoetis 32.43 Bn 30.75 Bn 1.05 Bn
4 Takeda Pharmaceutical 28.63 Bn 22.83 Bn 5.10 Bn
5 United Therapeutics 21.87 Bn 19.21 Bn 683.80 Mn
6 Viatris 18.98 Bn 18.09 Bn 1.46 Bn
7 Neurocrine Biosciences 15.43 Bn 15.04 Bn 935.80 Mn
8 Elanco Animal Health 12.02 Bn 11.49 Bn 798.00 Mn
9 Dr Reddys Laboratories 10.14 Bn 9.98 Bn -
10 Lantheus Holdings 6.52 Bn 5.93 Bn 241.86 Mn

Historic Data

Download Data
DateValue
Jun 30, 2026 454,000.00
Jun 30, 2026 454,000.00
Mar 31, 2026 1.54 Mn
Mar 31, 2026 1.54 Mn
Dec 31, 2025 -667,000.00
Dec 31, 2025 -667,000.00
Sep 30, 2025 1.93 Mn
Sep 30, 2025 1.93 Mn
Jun 30, 2025 2.31 Mn
Jun 30, 2025 2.31 Mn
Mar 31, 2025 -1.38 Mn
Mar 31, 2025 -1.38 Mn
Dec 31, 2024 -738,000.00
Dec 31, 2024 -738,000.00
Sep 30, 2024 -1.19 Mn
Sep 30, 2024 -1.19 Mn
Jun 30, 2024 -832,000.00
Jun 30, 2024 -832,000.00
Mar 31, 2024 2.76 Mn
Mar 31, 2024 2.76 Mn